Molecule

Unlocking liquid science markets through tokenized IP

[Molecule @Molecule_sci]

In early March, we met with the SEC Crypto Task Force.

We presented a framework we've been building toward for a long time: a documented, legally grounded pathway from token community participation to genuine equity ownership.

Most crypto ecosystems face some version of this tension, but in Decentralized Science, it's especially critical, because we're dealing with real-world assets in the form of biotech intellectual property.

Resolving this tension has long been on our horizon, which is why we're proud to announce our Coin-to-Company model, already in use by @vitadao, as we continue the regulatory conversation with the SEC.

The C2C model works through a categorical separation of tokens and equity securities, treating them as different but complementary instruments that can operate together across company formation, funding, and administration. Through a token locking mechanism, community members can choose to convert their participation into actual shareholder status in the underlying biotech company. All tokenholders remain part of a project-focused DAO throughout.

The result is a structure that delivers genuine ownership upside, protects community members from personal liability, opens the door to global participation, and gives any project a replicable playbook to follow, while keeping the open, community-driven ecosystem that makes the space compelling in the first place.

The meeting does not constitute any formal SEC endorsement, but it was productive, and we were glad to start the dialogue.

Read the announcement & let us know what you think.

[Molecule @Molecule_sci]

https://t.co/Ohe5Py1R8C

[Molecule @Molecule_sci]

The @vitarnabio team just closed a $200K raise to take their engineered suppressor platform into animal studies, building on the fundraising through Molecule Protocol.

You'll be able to catch @Mykalt45 speaking at @DeSciBerlin, fresh out of his $300M exit to @EliLillyandCo!

[Molecule @Molecule_sci]

The @vitarnabio team just closed a $200K raise to take their engineered suppressor platform into animal studies, building on the fundraising through Molecule Protocol.

You'll be able to catch @Mykalt45 speaking at @DeSciBerlin, fresh out of his $300M exit to @EliLillyandCo!

[Michael Torres @Mykalt45]

@artan_bio Raises $200,000 in Decentralized Funding to Advance Longevity Science Through Mutation-Specific Codon Su... https://t.co/WHvO0iaFej

Crypto + Biotech = A real thing. Excited for $vitarna token holders. We’re going to make waves in longevity. No need for $100Ms. CrossBridge flipped the script!

[Molecule @Molecule_sci]

Institutional capital arriving, AI-driven research compounding, and projects reaching clinical stages at a pace that would embarrass many traditionally funded biotechs.

Great write-up by @beakerdao

[Molecule @Molecule_sci]

Register to attend Vision Weekend → https://t.co/OaAs0BhlYV
Register to attend → https://t.co/kLjrXIuQZU https://t.co/0dPTJ5ha4e

[Molecule @Molecule_sci]

The @foresightinst Vision Weekend opens in London this week; three days of AI, longevity, and neurotech with researchers from @GoogleDeepMind, @Cambridge_Uni & @MIT.

Not in London? You'll be able to catch some of the Foresight team at @desciberlin on June 18–19!

[PeptAI @peptai_]

Every decision the agents make is publicly verifiable.

Every gate decision, tool call, pass, and failure is published openly on @molecule_sci. Agents mint their own IP NFTs and log the full audit trail on-chain.

Computational analysis stays publicly verifiable. Wet lab results can be held private until the team decides on disclosure. Agent announcements on new library designs and gate outcomes will be published on a weekly cadence.

[Molecule @Molecule_sci]

Institutional capital arriving, AI-driven research compounding, and projects reaching clinical stages at a pace that would embarrass many traditionally funded biotechs.

Great write-up by @beakerdao

[BEAKER 🧪 @beakerdao]

https://t.co/fbwpDRgp4f

[O'Ryan Health empowering at-home blood sampling. @ORyan_health]

Autism Spectrum Disorder (ASD) is a lifelong neurodevelopmental condition that shapes how individuals communicate, connect, and experience the world. Every person on the spectrum has unique strengths, challenges, and support needs.

Through innovative At Home research efforts, families can play an active role in helping scientists better understand autism in real-world settings, from developmental patterns to individualized support pathways.

By making participation more accessible, researchers can gather meaningful insights that may help improve understanding and future care.

In collaboration with the Molecule Science Foundation, the CRASD Token initiative supports a community-driven approach to advancing autism research.

Participation helps strengthen long-term scientific efforts focused on inclusion, early understanding, and building better support systems for individuals and families impacted by autism.

Every voice, every family, and every contribution helps shape a future with greater awareness, stronger communities, and more informed research.

Accessible for families. Meaningful for science.

Support the mission and learn more:

Link: https://t.co/KsMFS8A8tj

#AutismResearch
#ASDAwareness
#PediatricResearch
#OryanHealth
#HealthcareInnovation

[Michael Torres @Mykalt45]

And here’s a little teaser for my crypto-backed aging company, @artan_bio. Super cool biology we’re addressing! Anthony will be presenting our work at a conference in June. @vitarnabio @Molecule_sci @vitadao (currently not taking in dilutive capital!)

[Molecule @Molecule_sci]

Most real-world asset tokenization so far has focused on representing existing financial instruments onchain, treasuries, real estate, private credit.

Biotech IP was always going to be harder because it's not a static asset! It's a live research program that needs a company around it to progress, and a cap table that institutional capital can actually engage with.

The Coin-to-Company model is the missing layer that lets tokenized research sit alongside the rest of the RWA category, without forcing projects to choose between open community participation and a compliant path to equity.

Read the full framework → https://t.co/zZdKth75cE

[Molecule @Molecule_sci]

"Our Artemis platform truly embodies decentralized science." Dr. Tim Coleman, Architect of Operations at @ORyan_health, on bringing pediatric immune research into the home, one sample at a time.

Rare pediatric autoimmune disorders sit in one of the hardest corners of drug development: small patient populations, complex biology, and chronically underfunded research. Glad to be supporting @ORyan_health's work here.

Read the announcement
https://t.co/nLhcuBgnwE

[Molecule @Molecule_sci]

Proud to support @ORyan_health's research into rare pediatric autoimmune disease, exactly the kind of underfunded, high-impact science Molecule was built to enable.

[O'Ryan Health empowering at-home blood sampling. @ORyan_health]

Juvenile Dermatomyositis (JDM) is a rare autoimmune disease that can affect a child’s muscles, skin, and immune system.

Through O’Ryan Health’s Artemis platform, families can safely collect small At Home blood samples to help researchers better understand how JDM changes during flares, high therapy states, tapering, recovery, and everyday disease patterns.

In partnership with Molecule Science Foundation, the CRJDM initiative is helping build one of the largest decentralized single-cell immune datasets for JDM. Community participation through the CRJDM project helps support the coordination, transparency, and long-term stewardship needed to advance rare disease research collaboratively.

Every participating family contributes to a growing research effort designed to improve scientific understanding of JDM and support future breakthroughs in pediatric autoimmune disease research.

Simple for families. Powerful for research. 💜

👉 Learn more about the mission:

https://t.co/kMydwlCzPx

#CRJDMResearch
#JuvenileDermatomyositis
#RareDiseaseResearch
#DecentralizedScience
#ORyanHealth

[Molecule @Molecule_sci]

The goal is to build the largest decentralized single-cell immune dataset for JDM, a resource that could meaningfully reshape how the disease is understood and eventually treated.

Read the full announcement
https://t.co/wfXSqUGX0E

[Molecule @Molecule_sci]

Juvenile Dermatomyositis is a rare autoimmune disease where a child's immune system turns against their own tissue.

It has remained poorly understood for a structural reason: high-quality datasets don't exist. @ORyan_health is using the Molecule Protocol change that 🧵

[Molecule @Molecule_sci]

They will fund this work using a charitable token auction. Donors will receive one token for every $25 USD donation in either USD or USDC. Tokens can be used in the Coin to Company model as discussed in the project whitepaper, linked in the announcement.
https://t.co/ijnqxXaUqx

[DeSci.Berlin @DeSciBerlin]

1 month until DeSci Berlin!

The 5th edition focuses on two ideas reshaping research: scientific singularity and agentic science.

Calling all scientists, AI engineers, web3 builders, biotech founders!

Grab your spot and register now ↓

[Michael Torres @Mykalt45]

Look forward to being there. Will be sharing updates for @artan_bio $vitarna @vitarnabio

[Molecule @Molecule_sci]

Our flagship conference @desciberlin is just one month away.

Hosted in a brutalist church attached to an art gallery, it'll be our fifth year convening to discuss what the world looks like at the intersection of science and technology. Join us!

[DeSci.Berlin @DeSciBerlin]

Molecule Labs is coming to DeSci Berlin!

Maria Sanmartin, Senior Product Manager at @Molecule_sci, will cover key protocol and product features built over the past year, introduce Mira and the TRL Score, and tease upcoming product concepts.